Nasdaq GlobeNewswire

EPAM Acquires Continuum, Expanding Global Innovation, Design and Physical Product Development Capabilities

Del

NEWTOWN, Pa., March  15, 2018  (GLOBE NEWSWIRE) -- EPAM Systems, Inc. (NYSE:EPAM), a leading global provider of digital platform engineering and software development services, today announced its acquisition of Continuum, an innovation design firm headquartered in Boston with studios in Milan, Seoul, and Shanghai. Continuum partners with Fortune 500 clients in the healthcare, financial services, travel and hospitality, and consumer products industries to deliver value through four practices: Strategy, Physical/Digital Design, Technology and Made Real Lab.

The acquisition strengthens EPAM's innovation consulting capabilities and enhances existing digital and service design practices by introducing a human-centered approach to physical design and product development. Continuum's studios and the Made Real Lab are unique spaces that enable teams to collaborate throughout the entire iterative product development process by combining advanced prototyping technologies including mechanical, electrical and robotics engineering, together with AR/VR experimentation tools.

"The addition of Continuum expands our global presence in strategic markets in North America, Europe and Asia and brings to EPAM a deeper and more transformational, human-centered design approach, which will help us to better connect our customers' physical and digital business," said Arkadiy Dobkin, CEO & President, EPAM. "By introducing Continuum's approach into our network of EPAM Garages, we further mature our own innovation service offerings, while continuing to inspire and develop our people."

"By combining our capabilities, we will significantly improve our ability to turn innovative ideas, paired with disruptive technologies, into practical and scalable business solutions for our clients," said Gianfranco Zaccai, Founder of Continuum. "Joining EPAM enables us to introduce world-class innovation design and product development at scale to a Global 2000 client base, while bringing a comprehensive end-to-end offering to our existing clients."

Based on the estimated contribution of this acquisition, EPAM now expects revenue growth for full year 2018 to be at least 26% reported, or at least 24% in constant currency, after factoring in a 2% estimated currency tailwind, and GAAP EPS for the full year to now be at least $3.36 and Non-GAAP diluted EPS to now be at least $4.07. The Company's adjustments to its 2018 outlook relate solely to the impact of the Continuum acquisition.

To learn more about EPAM's digital strategy and experience design practice, visit us at https://www.epam.com/what-we-do/design.

About EPAM Systems
Since 1993, EPAM Systems, Inc. (NYSE:EPAM) has leveraged its core engineering expertise to become a leading global product development and digital platform engineering services company. Through its 'Engineering DNA' and innovative strategy, consulting, and design capabilities, EPAM works in collaboration with its customers to deliver innovative solutions that turn complex business challenges into real business opportunities. EPAM's global teams serve customers in over 25 countries across North America, Europe, Asia, and Australia. EPAM is a recognized market leader among independent research agencies and was ranked #12 in FORBES 25 Fastest Growing Public Tech Companies, as a top information technology services company on FORTUNE'S 100 Fastest-Growing Companies, and as a top UK Digital Design & Build Agency. Learn more at http://www.epam.com/ and follow us on Twitter @EPAMSYSTEMS and LinkedIn.

About Continuum
Continuum is a global innovation design firm. We design products, services, and experiences that improve people's lives, in small and large ways, while taking our clients' businesses into the future. Our clients range from start-ups to Fortune 500 brands across the healthcare, financial services, mobility, and consumer products sectors. For over 35 years, Continuum has been recognized for outstanding innovation and design for projects spanning from medical device and consumer product development and design, to customer experience design and innovation capability. Learn more at http://www.continuumInnovation.com and follow us on Twitter @_Continuum and LinkedIn.

Non-GAAP Financial Measures
EPAM supplements results reported in accordance with United States generally accepted accounting principles, referred to as GAAP, with non-GAAP financial measures. Management believes these measures help illustrate underlying trends in EPAM's business and uses the measures to establish budgets and operational goals, communicate internally and externally, for managing EPAM's business and evaluating its performance. Management also believes these measures help investors compare EPAM's operating performance with its results in prior periods. EPAM anticipates that it will continue to report both GAAP and certain non-GAAP financial measures in its financial results, including non-GAAP results that exclude stock-based compensation expense, write-offs and recoveries, amortization of purchased intangible assets, goodwill impairment, legal settlements, foreign exchange gains and losses, acquisition-related costs, certain other one-time charges, the impact of U.S. tax reform, excess tax benefits related to stock compensation and the related effect on income taxes. Management also compares operating results on a basis of "constant currency," which is also a non-GAAP financial measure. This measure excludes the effect of foreign currency exchange rate fluctuations by translating the current period revenues and expenses into U.S. dollars at the weighted average exchange rates of the prior period of comparison. Because EPAM's reported non-GAAP financial measures are not calculated according to GAAP, these measures are not comparable to GAAP and may not be comparable to similarly described non-GAAP measures reported by other companies within EPAM's industry. Consequently, EPAM's non-GAAP financial measures should not be evaluated in isolation or supplant comparable GAAP measures, but, rather, should be considered together with the information in EPAM's consolidated financial statements, which are prepared in accordance with GAAP.

Forward-Looking Statements
This press release includes statements which may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which are necessarily subject to risks, uncertainties, and assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ materially from those expressed or implied include general economic conditions and the factors discussed in our most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. EPAM undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities law.

EPAM SYSTEMS, INC. AND SUBSIDIARIES
Reconciliations of Guidance Non-GAAP Measures to Comparable GAAP Measures
 (Unaudited)

The below guidance constitutes forward-looking statements within the meaning of the federal securities laws and is based on a number of assumptions that are subject to change and many of which are outside the control of the Company. Actual results may differ materially from the Company's expectations depending on factors discussed in the Company's filings with the Securities and Exchange Commission.

Reconciliation of revenue growth at constant currency to revenue growth as reported under GAAP is presented in the table below:

    Full Year 2018  
Revenue growth at constant currency (at least) (1)   24 %  
Foreign exchange rates impact   2 %  
Revenue growth (at least)   26 %  
  1. Constant currency revenue results are calculated by translating current period projected revenues in local currency into U.S. dollars at the weighted average exchange rates of the comparable prior period.

Reconciliation of GAAP to non-GAAP diluted earnings per share guidance is presented in the table below:

    Full Year 2018  
GAAP diluted earnings per share (at least) $ 3.36    
Stock-based compensation expenses   1.01    
Included in cost of revenues   0.46    
Included in selling, general and administrative expenses   0.55    
Amortization of purchased intangible assets   0.14    
Foreign exchange loss   0.12    
Provision for income taxes:      
Tax effect on non-GAAP adjustments   (0.28)    
Excess tax benefits related to stock-based compensation   (0.28)    
Non-GAAP diluted earnings per share (at least) $ 4.07    

For media, contact: Danielle Ruess-Saltz
267.978.7688, danielle_ruess-saltz@epam.com For investor relations, contact: David Straube
david_straube@epam.com 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: EPAM Systems, Inc via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Taconic Biosciences Launches New Inflammatory Bowel Disease Models19.4.2018 14:00Pressemelding

RENSSELAER, N.Y., April 19, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered mouse model and service solutions, announces the launch of several new inflammatory bowel disease (IBD) animal models. As a fully-licensed provider of CRISPR/Cas9 gene editing technology, Taconic scientists knocked out the mouse Il10 gene to generate a spontaneous colitis mouse models. The new knockout models were created on Taconic's B6 (C57BL/6NTac) and BALB/c (BALB/cAnNTac) backgrounds, and are available at both the Excluded Flora (EF) and Germ Free (GF) health standards. Beyond the scientific benefits, Taconic is also making them easy to access by offering these models to commercial, contract research organization (CRO), and academic institutions under a simple label license. This represents a departure from the license requirements for Il10 knockouts from other animal model providers. "In order for animal models to drive drug discovery they need to be both

Cisco ACI Is Data Center Solution of Choice for Service Providers Worldwide19.4.2018 14:00Pressemelding

Service providers deliver new cloud services more quickly and offer superior customer experience with the help of Cisco Application Centric Infrastructure SAN JOSE, Calif., April 19, 2018 (GLOBE NEWSWIRE) -- Providing secure, differentiated and rapidly delivered cloud services to customers is a crucial requirement for today's service providers. To meet cloud infrastructure demands, global service providers are increasingly turning to the Cisco® Application Centric Infrastructure (Cisco ACI(TM)) , the industry-leading software-defined networking (SDN) solution. Cisco ACI reduces operational costs with an automated, policy-based programmable architecture, while improving scalability and security. In addition, new Cisco ACI multi-site management capability helps service providers to connect and manage multiple geographically distributed Cisco ACI fabrics and to move and manage workloads with a single pane of glass. Cisco ACI is being deployed worldwide by service providers such as NTT Com

FinancialForce Extends Professional Services Automation Leadership With its Spring 2018 Release19.4.2018 14:00Pressemelding

New features empower services organizations to run their businesses with greater predictability, assign best-fit resources at scale, and forecast projects with 360-degree insight. SAN FRANCISCO, April 19, 2018 (GLOBE NEWSWIRE) -- FinancialForce, the number one customer-centric ERP cloud vendor built on the Salesforce Platform, announced the availability of its latest version of Professional Services Automation, the highest customer-rated PSA solution for enterprise organizations. The Spring 2018 Release of PSA brings new functional capabilities to accelerate project staffing speed and accuracy; unify people and project data; enable better forecasting decisions; and enhance the overall user experience using the Salesforce Lightning framework. Fast, Accurate Resource Mapping With the Spring 2018 Release of PSA, project and resource managers can identify and assign best-fit resources with greater speed and accuracy. Through advanced skills filtering and search capabilities, including part

SpeeDx receives FDA clearance for Mycoplasma genitalium product19.4.2018 14:00Pressemelding

SYDNEY, Australia, April 19, 2018 (GLOBE NEWSWIRE) -- SpeeDx's Resistance Plus ® MG Positive Control kit has now been listed with the US Food and Drug Administration (FDA) for sale in the United States through the company's recently incorporated US entity, SpeeDx Inc. The announcement coincides with the FDA registration of the Australian parent company - SpeeDx Pty Ltd - as a Medical Device Manufacturing Establishment, and clinical trials remain on-track for the Resistance Plus MG assay.* The Resistance Plus MG Positive Control kit contains synthetic DNA to simulate Mycoplasma genitalium, as well as five mutations known to confer resistance to macrolide antibiotics. Macrolide-resistant M. genitalium is a challenging sexually transmitted infection (STI), and global management guidelines are currently being adapted to deal with the rise in resistance. "This is an important product in our portfolio," said Elisa Mokany, Chief Technology Officer for SpeeDx. "M. genitalium is very difficult

SEMAFO: Construction of Boungou Mine 91% Complete19.4.2018 13:00Pressemelding

Commissioning Advancing to Plan MONTREAL, April 19, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) announced that construction of the Boungou Mine in Burkina Faso is 91% complete, and commissioning activities are advancing well with 10% already completed at the end of March. Since launch of commissioning at the end of February, the crushing circuit equipment and water services have been tested and commissioned. The reclaim and grinding circuits, reagent and oxygen plants are also undergoing testing. Wet commissioning began at the end of March with the Corporation pumping water from the water storage facility to the raw water tanks for the processing plant. We are still in line to achieve our first gold pour early in the third quarter of 2018. As at March 31, 2018, the following milestones had been reached: Development on budget with US$194 million of the US$231 million capital expenditure incurred Construction of the mine 91% complete Completion of 98% of structural steel and

Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 201819.4.2018 13:00Pressemelding

Conference call scheduled for Thursday, April 26, 2018, at 8:30 a.m. ET UTRECHT, The Netherlands, April 19, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Company will report full year 2017 financial results on Thursday, April 26, 2018. Merus' management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, April 26, 2018, to discuss the financial results and recent clinical and corporate developments. To participate in the call, please dial (877) 260-1463 (U.S.) or (706) 643-5907 (international) and reference conference ID 6184636. A live webcast will be available on the Investors page of the Company's website, http://www.merus.nl. An archived webcast replay will be available for 90 days. About Merus N.V. Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeut

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom